Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK564292PMID: 33226755
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 1442472-39-0
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the use of ripretinib during breastfeeding. Because ripretinib and its metabolite are more than 99% bound to plasma proteins, the amounts in milk are likely to be low. However, their half-lives are long. The manufacturer recommends that mothers should not breastfeed during treatment with ripretinib and for 1 week after the final dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Ripretinib
CAS Registry Number
1442472-39-0
Drug Class
Breast Feeding
Antineoplastic Agents
Enzyme Inhibitors
Protein Kinase Inhibitors
Signal Transduction Inhibitors
Tyrosine Kinase Inhibitors
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- Review Selpercatinib.[Drugs and Lactation Database (...]Review Selpercatinib.. Drugs and Lactation Database (LactMed®). 2006
- Review Vandetanib.[Drugs and Lactation Database (...]Review Vandetanib.. Drugs and Lactation Database (LactMed®). 2006
- Review Olutasidenib.[Drugs and Lactation Database (...]Review Olutasidenib.. Drugs and Lactation Database (LactMed®). 2006
- Review Pemetrexed.[Drugs and Lactation Database (...]Review Pemetrexed.. Drugs and Lactation Database (LactMed®). 2006
- Review Ripretinib: A Review in Gastrointestinal Stromal Tumours as Fourth-or Later-Line of Therapy.[Drugs. 2022]Review Ripretinib: A Review in Gastrointestinal Stromal Tumours as Fourth-or Later-Line of Therapy.Fung S, Shirley M. Drugs. 2022 Oct; 82(15):1541-1548. Epub 2022 Oct 25.
- Ripretinib - Drugs and Lactation Database (LactMed®)Ripretinib - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...